Unrelated Hematopoietic Stem Cell Transplantation for Children with Acute Leukemia: Experience at a Single Institution

We evaluate the outcomes in children with acute leukemia who received allogeneic hematopoietic stem cell transplantation (HCT) using unrelated donor. Fifty-six children in complete remission (CR) received HCT from unrelated donors between 2000 and 2007. Thirty-five had acute myeloid leukemia, and 21 had acute lymphoid leukemia. Stem cell sources included bone marrow in 38, peripheral blood in 4, and cord blood (CB) in 14. Four patients died before engraftment and 52 engrafted. Twenty patients developed grade II-IV acute graft-versus-host disease (GVHD) and 8 developed extensive chronic GVHD. With median follow-up of 39.1 months, event free survival and overall survival were 60.4% and 67.5%, respectively, at 5 yr. Events included relapse in 10 and treatment-related mortality (TRM) in 10. The causes of TRM included sepsis in 4, GVHD in 4 (1 acute GVHD and 3 chronic GVHD), veno-occlusive disease in 1 and fulminant hepatitis in 1. Patients transplanted with CB had event free survival of 57.1%, comparable to 63.2% for those transplanted with other than CB. In conclusion, HCT with unrelated donors is effective treatment modality for children with acute leukemia. In children with acute leukemia candidate for HCT but lack suitable sibling donor, unrelated HCT may be a possible treatment option at the adequate time of their disease.

Key Words: Child; Acute Leukemia; Allogeneic Hematopoietic Stem Cell Transplantation; Unrelated Donor
MATERIALS AND METHODS

Between January 2000 and April 2007, 56 children with acute leukemia underwent allogeneic HCT from unrelated donors at the Asan Medical Center. The patients’ medical records were retrospectively reviewed and were analyzed as of April 2008. All 56 patients were transplanted in CR. Patients and donors were typed for HLA-A, -B, and -DRB1 by serological method between 2000 and 2002. High molecular resolution typing was performed for HLA-A, -B, -C and -DRB1 since 2003. Recipient-donor histocompatibility was determined by serology for HLA-A, -B, and -DRB1 antigens.

The patients were hospitalized in laminar airflow rooms. To prevent infection, all patients received prophylactic acyclovir and itraconazole or fluconazole. Granulocyte colony-stimulating factor (G-CSF) was administered to most patients. The myeloablative conditioning regimen was administered, and stem cells were infused through a central venous catheter on day zero. All patients received prophylactic treatment using cyclosporine with methotrexate or prednisone to prevent acute GVHD. The day of engraftment was defined as the first of 3 consecutive days on which the granulocyte count exceeded $0.5 \times 10^9/L$ and the last of 7 consecutive days when the platelet count $>20 \times 10^9/L$ without transfusion support. Donor engraftment was documented by short-tandem repeat polymerase chain reaction (STR-PCR), which was usually performed on day 28 after transplantation. Acute and chronic GVHD were diagnosed and graded according to standard criteria (13-15). Patients were not considered to be evaluable for acute GVHD if they died before engraftment or for chronic GVHD if they died before day 100 after transplantation.

Overall survival (OS) was defined as the time between transplantation and death due to any causes. EFS was defined as the time interval from transplantation to first event, either relapse or death in complete remission. TRM was defined as death from any cause other than relapse. The Kaplan-Meier method was used to summarize estimates of OS and EFS (16), and outcomes were compared by means of the exact log-rank test. The Student t test was used to compare the median age at diagnosis and HCT, the white blood cell count at diagnosis, and the number of days of engraftment. The chi-square test was used to compare the incidence of GVHD. Univariate analysis of prognostic factors was examined by using the approach of Kaplan and Meier and of Cox regression for fixed and time-dependent factors, respectively (19). All factors were considered by using defined discrete categories. Factors significant in univariate analysis were considered for inclusion in multivariate Cox regression models. P values <0.05 were considered as statistically significant. All statistical analyses were conducted with SPSS software (Statistical Package for the Social Science, version 12.0, SSPS Inc, Chicago, IL, U.S.A.).

RESULTS

Characteristics of patients at transplantation

The characteristics of patients are shown in Table 1. Of 56 patients, 35 had AML (29 CR1, 6 CR2), and 21 had ALL (10 CR1, 7 CR2, 4 CR3). Overall the median age at transplantation was 6.3 yr and 37 were male. Thirty-nine patients received HCT in CR1, 17 beyond CR1. Of 35 patients with AML, 10 had t(8;21) of whom 7 were in CR1 and 1 was CR2, 2 had t(15;17) in CR2 and none had inv (16). Of 21 patients with ALL, 4 had t(9;22), 4 had infant ALL of whom 3 had 11q23 abnormalities, 1 had very high initial white cells over 500,000/μL, 1 had secondary ALL and 11 had early bone marrow relapse. Stem cell sources included bone marrow (BM)

Table 1. Clinical characteristics of patients at the time of transplantation

| Characteristics | AML | ALL |
|-----------------|-----|-----|
| No. of patients  | 35  | 21  |
| Age (yr) at HCT  | 6.3 (0.6-15.4) | 6.9 (1.2-18.4) |
| Gender (male:female) | 24:11 | 13:8 |
| Cytogenetics    |     |     |
| t(8;21)         | 10  | 0   |
| inv(16)         | 0   | 0   |
| t(15;17)*       | 2   | 0   |
| Monosomy 7      | 2   | 0   |
| Complex (>5 abnormal) | 2   | 0   |
| 11q23 abnormalities | 1 | 5   |
| t(12;21)        | 0   | 1   |
| t(9;22)         | 0   | 4   |
| Normal          | 5   | 3   |
| Other abnormalities | 11 | 5   |
| Unknown         | 2   | 3   |
| Phase of disease|     |     |
| CR1             | 29  | 10  |
| ≥CR2            | 6   | 11  |
| Stem cell sources|     |     |
| Bone marrow     | 27  | 11  |
| Peripheral blood| 0   | 4   |
| Cord blood      | 8   | 6   |
| Conditioning regimen |     |     |
| Bu/Cy           | 26  | 3   |
| TBI/Cy          | 0   | 11  |
| Other*          | 9   | 7   |
| GVHD prophyaxis |     |     |
| Cyclosporine/methotrexate | 27 | 15 |
| Cyclosporine/prednisone | 5 | 5   |
| Cyclosporine/MMF | 3  | 1   |

* CR2 at transplantation; 1 Bu/Cy/ATG (3), TBI/Cy/ATG (4), BuFlu/ATG (3), Cy/Flu/ATG (2), TBI/VP16 (1), Bu/Cy/VP16 (1), TBI/CyFlu/MMF (1), BuCy/ATG/VP16 (1). AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; No., number; HCT, hematopoietic stem cell transplantation; CR, complete remission; Bu, busulfan; Cy, cyclophosphamide; TBI, total body irradiation; ATG, anti-thymocyte globulin; Flu, fludarabine; GVHD, graft-versus-host disease; MMF, mycophenolate mofetil.
in 38, peripheral blood (PB) in 4, and cord blood (CB) in 14. All of the 42 patients who underwent HCT with BM or PB were matched at HLA-A, -B, and -DRB1 antigens. In contrast, only two of 14 CB transplantation received grafts that were matched at HLA-A, -B, and -DRB1 antigens. Busulfan containing regimen was the most common conditioning for AML and total body irradiation (TBI)-based regimen for ALL. The median infused cell doses were \(9.7 \times 10^6\) CD34+ cells/kg for non-CB transplantation and \(1.6 \times 10^5\) CD34+ cells/kg for CB transplantation, respectively. The transplantation outcomes are shown in Table 2.

**Engraftment**

Fifty-two of the 56 patients achieved a sustained granulocyte count greater than \(0.5 \times 10^9/L\) at a median of 16 days (10-48) post transplantation. Three patients, 2 CB transplantation and 1 non-CB transplantation, died before day 28 without recovery of granulocyte count greater than \(0.5 \times 10^9/L\). One patient who received CB transplantation died on day 110 of sepsis with a granulocyte count <\(0.5 \times 10^9/L\). Fifty of the 56 patients achieved a sustained platelet count greater than \(20 \times 10^9/L\) at a median of 33 days (16-171) post transplantation. CB transplantation had significantly slower neutrophil and platelet engraftment than transplantation using BM or PB (\(P=0.002\), <0.001, respectively; Fig. 1).

**Acute and chronic GVHD**

Twenty of 52 evaluable patients developed grades II-IV acute GVHD. Two had grade IV acute GVHD and all those died of complications related to GVHD. The cumulative incidence of acute GVHD grade II-IV in evaluable patients at day 100 post-transplantation was 40.3%. Both univariate and multivariate analyses revealed that early engraftment before 15 days post transplantation was associated with higher incidence of acute GVHD grade II or above (\(P=0.004\), Table 3). Chronic GVHD was developed in 23 of 49 evaluable patients including clinically extensive chronic GVHD in 8

---

**Table 2. Outcomes after transplantation**

| Outcomes                        | AML (range) | ALL (range) |
|---------------------------------|-------------|-------------|
| Median day to engraftment       |             |             |
| Neutrophil (range)              | 16 (10-48)  | 17 (11-43)  |
| Platelet (range)                | 33 (20-171) | 31 (16-147) |
| GVHD                            |             |             |
| Acute (evaluable)               | (34)        | (18)        |
| 0-1                             | 20          | 12          |
| 2-4                             | 14          | 6           |
| Chronic (evaluable)             | (31)        | (18)        |
| Limited                         | 9           | 6           |
| Clinical extensive               | 3           | 5           |
| Treatment-related mortality     | 5           | 5           |
| Relapse-related mortality       | 8           | 2           |

AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; GVHD, graft-versus-host disease.

---

**Table 3. Risk factors for acute GVHD (Grade II-IV)**

| Factors             | Patients | Incidence of aGVHD | Univariate \(P\) value | Multivariate \(P\) value |
|---------------------|----------|--------------------|-------------------------|--------------------------|
| Disease             |          |                    |                         |                          |
| ALL                 | 18       | 36.2%              |                         |                          |
| AML                 | 34       | 43.9%              |                         |                          |
| Phase of disease    |          |                    | 0.36                    |                          |
| CR1/2               | 49       | 38.6%              |                         |                          |
| CR3                 | 3        | 66.7%              |                         |                          |
| Stem cell source    |          |                    | 0.3                     |                          |
| BM/PB               | 41       | 44.0%              |                         |                          |
| CB                  | 11       | 27.3%              |                         |                          |
| Engraftment         |          |                    | <0.001                  | 0.004                    |
| ≤ 15 days           | 22       | 63.3%              |                         |                          |
| >15 days            | 30       | 24.4%              |                         |                          |

aGVHD, acute graft-versus-host disease; AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; CR, complete remission; BM, bone marrow; PB, peripheral blood; CB, cord blood.

---

**Fig. 1.** Engraftment rate of neutrophils (A) and platelets (B) according to stem cell sources.
Treatment-related mortality

Ten patients died of causes not related to recurrent leukemia. The causes of TRM included sepsis in 4, GVHD in 4 (1 acute GVHD and 2 chronic GVHD), veno-occlusive disease in 1 and fulminant hepatitis in 1. One patient who had late graft failure is alive in CR at 2 yr post-transplantation. The Kaplan-Meier estimates of TRM at 100 days, 1 yr and 2 yr were 3.6%, 15%, and 19.5%, respectively. Both univariate and multivariate analyses revealed that phase of disease beyond CR1/2 was associated with higher TRM ($P=0.04$, Table 4).

Table 4. Risk factors for TRM

| Factors          | Patients | TRM @ SYR | Univariate P value | Multivariate P value |
|------------------|----------|-----------|--------------------|----------------------|
| Disease          |          |           |                    |                      |
| ALL              | 21       | 26.0%     | 0.38               |                      |
| AML              | 35       | 15.6%     |                    |                      |
| Phase of disease |          |           | 0.003              | 0.04                 |
| CR1/2            | 52       | 14.3%     |                    |                      |
| CR3              | 4        | 75.0%     |                    |                      |
| Stem cell source |          |           | 0.17               |                      |
| BM/PB            | 42       | 15.8%     |                    |                      |
| CB               | 14       | 30.7%     |                    |                      |
| Acute GVHD       |          |           | 0.022              | 0.09                 |
| Grade 0/I        | 32       | 3.1%      |                    |                      |
| Grade II-IV      | 20       | 28.1%     |                    |                      |

TRM, treatment-related mortality; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CR, complete remission; BM, bone marrow; PB, peripheral blood; CB, cord blood; GVHD, graft-versus-host disease.

Relapse

Eight patients with AML and 2 with ALL relapsed at a median of 6.4 (2.7-58.2) months post-transplantation. Eight of 10 patients who relapsed died of progressive disease. One patient who had extramedullary relapse at 2.8 months post-transplantation received donor lymphocyte infusion and he survives 38.4 months post-transplantation in remission. The estimated relapse rate at 5 yr was 24.9%. Although none of 7 patients who have greater than or equal to grade III acute GVHD relapsed, acute GVHD over grade II was not associated with decreased relapse rate (0% vs. 28.6%; $P=0.21$).

Overall and event free survival

With a median follow-up of 39.1 months (12.7-101.1), the estimates of EFS and OS for all patients were 60.4% (ALL 65.9%, AML 58.4%) and 67.5% (ALL 62.9%, AML 69.9%), respectively (Fig. 2). Patients transplanted with CB had EFS of 57.1%, which was comparable to 65.2% for those transplanted with stem cells other than CB. There was no significant difference of EFS according to phase of disease, stem cell sources, and acute or chronic GVHD.

DISCUSSION

Although HCT is a curative therapy for pediatric acute leukemia including relapsed ALL, ALL with very high risk of relapse at diagnosis and AML except certain group of patient who had Down syndrome or acute promyelocytic leukemia, only a limited number of children have a matched sibling donors (11). The major obstacles for unrelated donor HCT are high treatment related morbidity or mortality as well as high incidence of GVHD. Balduzzi et al. (12) reported the Seattle's experience on unrelated donor bone marrow transplantation for 88 children mostly with hematologic malignancies. Acute GVHD developed in more than 80% of evaluable patients and chronic GVHD in more than 60%. Twenty-five (28%) of 88 patients died in remission and most
of the death were due to infections associated with GVHD. Davies et al. (13) also reported high TRM of 53% in patients receiving matched marrow and 65% in recipients of mismatched marrow. In that study, TRM at day 100 was 36%. With better supportive care including strategy to infectious diseases and prophylaxis for GVHD as well as improvement of HLA typing methods resulting in low graft failure and less severe GVHD, the survival of unrelated donor HCT approaches those of matched sibling donor. Furthermore, the GVL effects of unrelated donor HCT can provide a therapeutic advantage in hematologic malignancies with high risk of relapse after transplantation. In the present study, the graft failure rate including early death, the incidence of grades II-IV acute GVHD and extensive chronic GVHD were 7.1%, 40.3%, and 16.3%, respectively, and the TRM at 100 days was 3.7% which are quite comparable to those of matched sibling donor transplantation (14, 15). The multivariate analysis revealed that early engraftment before 15 days post transplantation was associated with higher incidence of acute GVHD and phase of disease beyond CR1/2 was associated with higher TRM.

In childhood ALL, chemotherapy provides excellent outcome and HCT is not usually indicated in first remission. But some patients with very high-risk features such as age less than 12 months at presentation or certain type of cytogenetic abnormalities require transplantation in first remission (3, 4, 20-22). Although HCT using matched sibling donor had shown uniformly satisfactory survival, the outcome for unrelated HCT has been variable ranging 40% to 70%. In our study, among 10 patients with ALL who received unrelated HCT in CR1, only 2 died of complications related to transplantation at 0.3 months post-transplantation but all others are alive in remission with a median follow-up of 29 months. Relapsed ALL is another indication of HCT, especially for patients with early marrow relapse (23). In this study, among 11 patients who received HCT at relapse, 2 died of disease progression, 3 died of causes related to treatment, and 6 survive in remission with a median follow-up of 29 months. Our study showed that unrelated HCT could be considered in high-risk or relapsed childhood ALL when they lack matched sibling donor although our study have some limitations of small number of patients, short follow-up period and heterogeneous patients.

While there are some controversies for the best post-remission treatment for childhood AML, several reports revealed the therapeutic advantage of HCT compared to chemotherapy (9). HCT could be performed in first remission, especially for patients with unfavorable features if the patient has available matched sibling donor. Given the poor prognosis in childhood AML when treated with chemotherapy alone, HCT using alternative donors could be a possible treatment option for patients who do not have matched sibling donor. We have a policy to perform HCT in childhood AML without Down syndrome or t(15;17) who achieved CR if they have any available donor including unrelated source. In our study the EFS for children who received in CR1 was 59.1% and for children in CR2 was 50.0%.

Recent studies of HCT using umbilical cord blood report promising results in childhood acute leukemia (24, 25). We found that the outcome was comparable in patients receiving cord blood or stem cells other than cord blood.

As acute GVHD and TRM are still major obstacles for unrelated donor HCT, the more comprehensive approach and advance in donor selection, prophylaxis and treatment of GVHD and supportive care including infections are still required to improve the outcome in unrelated setting. In addition, To further clarify the role of unrelated HCT for children with acute leukemia, prospective nation-wide study including larger number of patients is warranted.

In conclusion, our study suggests that the unrelated HCT for children with acute leukemia is an effective treatment modality, and for the patients who need HCT but lack suitable sibling donor, HCT using unrelated donor including cord blood may be a possible option in the adequate time of disease.

REFERENCES

1. Chessells JM. Relapsed lymphoblastic leukaemia in children: a continuing challenge. Br J Haematol 1998; 102: 423-38.
2. Pui CH, Evans WE. Acute lymphoblastic leukaemia. N Engl J Med 1998; 339: 605-15.
3. Heerema NA, Nachman JB, Sather HN, Sensel MG, Lee MK, Hutchinson R, Lange BJ, Steinherz PG, Bostrom B, Gaynon PS, Uckun F. Hypodiploidy with less than 45 chromosomes confers adverse risk in childhood acute lymphoblastic leukaemia: a report from the children’s cancer group. Blood 1999; 94: 4036-45.
4. Johansson B, Moorman AV, Haas OA, Watmore AE, Cheung KL, Swanton S, Secker-Walker LM. Hematologic malignancies with t(4; 11)(q21;q23)--a cytogenetic, morphologic, immunophenotypic and clinical study of 183 cases. European 11q23 Workshop participants. Leukemia 1998; 12: 779-87.
5. Uckun FM, Nachman JB, Sather HN, Sensel MG, Kraft P, Steinherz PG, Lange B, Hutchinson R, Reaman GH, Gaynon PS, Heerema NA. Clinical significance of Philadelphia chromosome positive pediatric acute lymphoblastic leukemia in the context of contemporary intensive therapies: a report from the Children’s Cancer Group. Cancer 1998; 83: 2030-9.
6. Ravindrunath Y, Chang M, Steuber CP, Becton D, Dahl G, Civin C, Camitta B, Carroll A, Raimondi SC, Weinstein HI; Pediatric Oncology Group. Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000. Leukemia 2005; 19: 2101-16.
7. Gibson BE, Wheatley K, Hann IM, Stevens RF, Webb D, Hills RK, De Graaf SS, Harrison CJ. Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia 2005; 19: 2130-8.
8. Creutzig U, Zimmermann M, Ritter J, Reinhardt D, Hermann J, Henze G, Jürgens H, Kabisch H, Reiter A, Riehm H, Gaden H, Schellong G. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia 2005; 19: 2030-42.

9. Woods WG, Neudorf S, Gold S, Sanders J, Buckley JD, Barnard DR, Dusenbery K, D’Sware J, Arthur DC, Lange BJ, Kobrinsky NL; Children’s Cancer Group. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood 2001; 97: 56-62.

10. Becton D, Dahl GV, Ravindranath Y, Chang MN, Behm FG, Rai

11. Kernan NA, Bartsch G, Ash RC, Beatty PG, Champlin R, Filipovich AH, Glave P, Perkins HA, Phillips GL, Sanders J, Stromeck D, Thomas ED, Blume KG. Analysis of 462 transplantations from unrelated donors facilitated by the national marrow donor program. N Engl J Med 1993; 328: 593-602.

12. Balduzzi A, Gooley T, Anasetti C, Sanders JE, Martin PJ, Petersdorf ED, Blume KG. Pediatric Oncology Group. Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421. Blood 2006; 107: 1315-24.

13. Kernan NA, Bartsch G, Ash RC, Beatty PG, Champlin R, Filipovich A, Gajewski J, Hansen JA, Henslee-Downey J, McCullough J, McGlave P, Perkins HA, Phillips GL, Sanders J, Stromeck D, Thomas ED, Blume KG. Analysis of 462 transplantations from unrelated donors facilitated by the national marrow donor program. N Engl J Med 1993; 328: 593-602.

14. Saarinen-Pihkala UM, Gustafsson G, Ringden O, Heilmann C, Glomsten A, Lønnerholm G, Abrahamsson J, Bekassy AN, Schroeder H, Mellander L; Nordic Society of Pediatric Hematology and Oncology. No disadvantage in outcome of using matched unrelated donors as compared with matched sibling donors for bone marrow transplantation in children with acute lymphoblastic leukemia in second remission. J Clin Oncol 2001; 19: 3404-14.

15. Al-Kasim FA, Thornley I, Rolland M, Lau W, Tsang R, Freedman MH, Saunders EF, Calderwood S, Doyle JJ. Single-centre experience with allogeneic bone marrow transplantation for acute lymphoblastic leukaemia in childhood: Similar survival after matched-related and matched-unrelated donor transplants. Br J Haematol 2002; 116: 483-90.

16. Moore J, Nixon-Smith I, Goh K, Ma D, Bradstock K, Szer J, Durant S, Schwarer A, Barty P, Hermann R, Dodds A. Equivalent survival for sibling and unrelated donor allogeneic stem cell transplan-
tation for acute myelogenous leukemia. Biol Blood Marrow Transplant 2007; 13: 601-7.

17. Dahlke J, Kröger N, Zabelina T, Ayuk F, Felse N, Wolschke C, Waschke O, Schieder H, Renges H, Krüger W, Knaell A, Hinke A, Erttmann R, Kabisch H, Zander AR. Comparable results in patients with acute lymphoblastic leukemia after related and unrelated stem cell transplantation. Bone Marrow Transplant 2006; 37: 153-63.

18. Neudorf S, Sanders J, Kobrinsky N, Alonzo TA, Buxton AB, Gold S, Barnard DR, Wallace JD, Kalousek D, Lange BJ, Woods WG. Allogeneic bone marrow transplantation for children with acute myelo-
cytic leukemia in first remission demonstrates a role for graft ver-
sus leukemia in the maintenance of disease-free survival. Blood 2004; 103: 3655-61.

19. Cox DR. Regression models and life tables. J R Stat Soc B 1972; 34: 187-220.

20. Biondi A, Cinino G, Pieters R, Pui CH. Biological and therapeutic aspects of infant leukemia. Blood 2000; 96: 24-33.

21. Arico M, Valsecchi MG, Camitta B, Schrappe M, Chessells J, Bar- ruchel A, Gaynor P, Silverman L, Janka-Schaub G, Kamps W, Pui CH, Masera G. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 2000; 342: 998-1006.

22. Behm FG, Raimondi SC, Frestedt JL, Liu Q, Crist WM, Downing JR, Rivera GK, Kersey JH, Pui CH. Rearrangement of the MLL gene confers a poor prognosis in childhood acute lymphoblastic leukemia, regardless of presenting age. Blood 1996; 87: 2870-7.

23. Badell I, Muñoz A, Ortega J, Martinez A, Madero L, Buroe E, Ver-
deguer A, Fernandez-Delgado R, Cubells J, Soledad-Maldonado M, Olivé T, Sastre A, Baro J, Diaz MA; Spanish Working Party for BMT in Children (GETMON). Long-term outcome of allogeneic or autol-
ogous haemopoietic cell transplantation for acute lymphoblastic leu-
kaemia in second remission in children. GETMON experience 1983-1998. Bone Marrow Transplant 2005; 35: 895-901.

24. Michel G, Rocha V, Chevet S, Arcese W, Chan KW, Filipovich A, Takahashi TA, Vowels M, Ortega J, Bordignon P, Shaw PJ, Yaniv I, Machado A, Pimentel P, Fagioli F, Verdeguer A, Jouet JP, Diez B, Ferreira E, Pasquini R, Rosenthal J, Sievers E, Messina C, Iori AP, Garnier F, Ionescu I, Locatelli F, Gluckman E; Eurocord Group. Unre-
lated cord blood transplantation for childhood acute myeloid leu-
kaemia: a Eurocord Group analysis. Blood 2003; 102: 4290-7.

25. Rocha V, Cornish J, Sievers EL, Filipovich A, Locatelli F, Peters C, Remberger M, Michel G, Arcese W, Dallorso S, Tiedemann K, Busca A, Chan KW, Kato S, Ortega J, Vowels M, Zander A, Souillet G, Oakill A, Woolfrey A, Pay AL, Green A, Garnier F, Ionescu I, Wer-
et P, Sirchia G, Rubinstein P, Chevet S, Gluckman E. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplan-
tions in children with acute leukemia. Blood 2001; 97: 2962-71.